NASDAQ:ACCD Accolade (ACCD) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ACCD Stock Alerts $9.19 -0.21 (-2.23%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$8.86▼$9.4150-Day Range$8.25▼$12.3652-Week Range$6.33▼$17.00Volume769,255 shsAverage Volume718,708 shsMarket Capitalization$711.40 millionP/E RatioN/ADividend YieldN/APrice Target$15.53 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Accolade alerts: Email Address Accolade MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside69.0% Upside$15.53 Price TargetShort InterestHealthy4.06% of Shares Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment-0.09Based on 16 Articles This WeekInsider TradingSelling Shares$73,872 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.33) to ($1.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.07 out of 5 starsBusiness Services Sector59th out of 304 stocksBusiness Services, Not Elsewhere Classified Industry27th out of 81 stocks 3.4 Analyst's Opinion Consensus RatingAccolade has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 12 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAccolade has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.06% of the outstanding shares of Accolade have been sold short.Short Interest Ratio / Days to CoverAccolade has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Accolade has recently decreased by 2.18%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAccolade does not currently pay a dividend.Dividend GrowthAccolade does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccolade has received a 76.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private oncologist's appointments", "Private neurologist's appointments", "Private general practice doctor's diagnostic online appointments", "Private cardiologist's online appointments", and "Private gynaecologist's online appointments" products. See details.Environmental SustainabilityThe Environmental Impact score for Accolade is -0.89. Previous Next 1.1 News and Social Media Coverage News SentimentAccolade has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Business Services companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Accolade this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ACCD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accolade insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,872.00 in company stock.Percentage Held by InsidersOnly 8.30% of the stock of Accolade is held by insiders.Percentage Held by Institutions84.99% of the stock of Accolade is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accolade are expected to grow in the coming year, from ($1.33) to ($1.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accolade is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accolade is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAccolade has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Accolade Stock (NASDAQ:ACCD)Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. It also provides medical opinion and decision support services; and technology and administrative services to the medical practice PCs providing virtual primary care services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.Read More ACCD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACCD Stock News HeadlinesApril 25, 2024 | sfgate.comAccolade: Fiscal Q4 Earnings SnapshotApril 25, 2024 | msn.comACCD Stock Earnings: Accolade Misses EPS, Beats Revenue for Q4 2024April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 25, 2024 | finance.yahoo.comAccolade Inc (ACCD) Surpasses Revenue Expectations and Narrows Losses in Fiscal Q4 and Full ...April 25, 2024 | globenewswire.comAccolade Announces Results for Fiscal Fourth Quarter and Full Year 2024April 24, 2024 | investing.comStifel cuts Accolade stock price target to $13, maintains buy ratingApril 23, 2024 | finance.yahoo.comAccolade, Inc. (ACCD)April 23, 2024 | americanbankingnews.comAccolade (NASDAQ:ACCD) Price Target Cut to $13.00 by Analysts at Stifel NicolausApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 22, 2024 | benzinga.comAlphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For MondayApril 21, 2024 | investing.comAccolade CEO Rajeev Singh sells $3.1k in stockApril 18, 2024 | morningstar.comAccolade Inc Ordinary SharesApril 18, 2024 | americanbankingnews.comAccolade (ACCD) Scheduled to Post Quarterly Earnings on ThursdayApril 14, 2024 | uk.investing.comAccolade CFO exercises options, sells shares for tax obligationsApril 5, 2024 | seekingalpha.comAccolade: Staying Bullish On Favorable DevelopmentsApril 3, 2024 | finance.yahoo.comAccolade to Announce Fiscal Fourth Quarter 2024 Financial ResultsApril 1, 2024 | finance.yahoo.comRecent uptick might appease Accolade, Inc. (NASDAQ:ACCD) institutional owners after losing 24% over the past yearMarch 20, 2024 | prnewswire.comAccolade Wins 2024 Artificial Intelligence Excellence AwardMarch 19, 2024 | businesswire.comNational Accolade Bestowed on Arkansas-Based Provider: ‘Best Rural High Speeds'March 19, 2024 | prnewswire.comAccolade Promotes Kelsi McDonald Harris to Chief People OfficerMarch 17, 2024 | finance.yahoo.comACCD Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comACCD Apr 2024 12.500 callMarch 15, 2024 | barrons.comAccolade Inc.March 12, 2024 | proactiveinvestors.comChesapeake Bank receives AARP accolade for combatting financial exploitationFebruary 28, 2024 | globenewswire.comAccolade To Present at Upcoming Investor ConferencesFebruary 27, 2024 | prnewswire.comAccolade Welcomes Brightline to Trusted Partner EcosystemFebruary 26, 2024 | msn.comLeerink Partners Initiates Coverage of Accolade (ACCD) with Outperform RecommendationSee More Headlines Receive ACCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accolade and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/27/2023Today4/25/2024Next Earnings (Confirmed)4/25/2024Fiscal Year End2/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Business services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:ACCD CUSIPN/A CIK1481646 Webaccolade.com Phone206-926-8100FaxN/AEmployees2,370Year FoundedN/APrice Target and Rating Average Stock Price Target$15.53 High Stock Price Target$19.00 Low Stock Price Target$12.00 Potential Upside/Downside+69.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-459,650,000.00 Net Margins-31.59% Pretax Margin-31.48% Return on Equity-27.27% Return on Assets-14.36% Debt Debt-to-Equity Ratio0.48 Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$363.14 million Price / Sales1.96 Cash FlowN/A Price / Cash FlowN/A Book Value$6.51 per share Price / Book1.41Miscellaneous Outstanding Shares77,410,000Free Float70,983,000Market Cap$711.40 million OptionableOptionable Beta2.08 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Rajeev Singh (Age 56)Chairman of the Board & CEO Comp: $778.5kMr. Robert Cavanaugh (Age 55)President Comp: $582.63kMr. Stephen H. Barnes CPA (Age 52)CFO & Treasurer Comp: $557.5kMs. Kristen BruzekSenior Vice President of OperationsMr. Colin McHugh (Age 45)Chief Accounting Officer Mr. Todd FriedmanSenior Vice President of Investor RelationsMr. Richard Eskew (Age 49)Executive VP, General Counsel, CCO & Secretary Ms. Kelsi McDonald HarrisChief People Officer & Senior Vice PresidentMr. Drew GarnerExecutive Vice President of EngineeringDr. Shantanu Nundy M.B.A.M.D., Executive VP of Care Delivery, Chief Health Officer & Member of the Medical Advisory BoardMore ExecutivesKey CompetitorsInternational Money ExpressNASDAQ:IMXIViadNYSE:VVIConduentNASDAQ:CNDTPaysafeNYSE:PSFELiquidity ServicesNASDAQ:LQDTView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 2,000 shares on 4/25/2024Ownership: 0.000%Sumitomo Mitsui Trust Holdings Inc.Sold 104,934 shares on 4/19/2024Ownership: 2.193%Rajeev SinghSold 355 sharesTotal: $3,131.10 ($8.82/share)Stephen H BarnesSold 109 sharesTotal: $961.38 ($8.82/share)Robert N CavanaughSold 141 sharesTotal: $1,243.62 ($8.82/share)View All Insider TransactionsView All Institutional Transactions ACCD Stock Analysis - Frequently Asked Questions Should I buy or sell Accolade stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACCD shares. View ACCD analyst ratings or view top-rated stocks. What is Accolade's stock price target for 2024? 16 Wall Street analysts have issued 1-year target prices for Accolade's shares. Their ACCD share price targets range from $12.00 to $19.00. On average, they anticipate the company's share price to reach $15.53 in the next twelve months. This suggests a possible upside of 69.0% from the stock's current price. View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts. How have ACCD shares performed in 2024? Accolade's stock was trading at $12.01 at the beginning of the year. Since then, ACCD stock has decreased by 23.5% and is now trading at $9.19. View the best growth stocks for 2024 here. How were Accolade's earnings last quarter? Accolade, Inc. (NASDAQ:ACCD) posted its earnings results on Thursday, April, 27th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.01. The company earned $99.03 million during the quarter, compared to analyst estimates of $99.44 million. Accolade had a negative net margin of 31.59% and a negative trailing twelve-month return on equity of 27.27%. Accolade's revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the company posted ($0.59) EPS. What ETFs hold Accolade's stock? ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS), Fidelity Digital Health ETF (FDHT) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has Accolade issued on next quarter's earnings? Accolade issued an update on its first quarter 2025 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $103.0 million-$106.0 million, compared to the consensus revenue estimate of $110.9 million. What is Rajeev Singh's approval rating as Accolade's CEO? 152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees. What other stocks do shareholders of Accolade own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC). When did Accolade IPO? Accolade (ACCD) raised $176 million in an initial public offering on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers. Who are Accolade's major shareholders? Accolade's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.19%), Los Angeles Capital Management LLC (0.07%), Simplex Trading LLC (0.00%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh and Stephen H Barnes. View institutional ownership trends. How do I buy shares of Accolade? Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACCD) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accolade, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.